S1P (York Pharma)(S1P (York Pharma)) - 药物靶点：S1PR1_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Sphingosine-1-phosphate (Berlin Free University)、Sphingosine-1-phosphate (York Pharma)

+ [1]

靶点

S1PR1

作用机制

S1PR1激动剂(鞘氨醇-1-磷酸受体-Edg-1激动剂)

治疗领域

皮肤和肌肉骨骼疾病

在研适应症-

非在研适应症

皮肤疾病

原研机构

Freie Universität Berlin

在研机构-

非在研机构

York Pharma Plc

Freie Universität Berlin

最高研发阶段终止药物发现

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

2

项与 S1P (York Pharma) 相关的临床试验

JPRN-UMIN000004497 / RecruitingIIT

Clinical Significance of Sphingosine-1-Phosphate in the Evaluation of Endothelial Function and Cardiovascular Risk in Hypertension - SEE-THRU BP

开始日期2011-03-01

申办/合作机构-

JPRN-UMIN000004116 / RecruitingIIT

Clinical Significance of Sphingosine-1-Phosphate in the Evaluation of Endothelial Function and Cardiovascular Risk in Dyslipidemia - SEE-THRU Lipid

开始日期2010-09-01

申办/合作机构-

100 项与 S1P (York Pharma) 相关的临床结果

登录后查看更多信息

100 项与 S1P (York Pharma) 相关的转化医学

登录后查看更多信息

100 项与 S1P (York Pharma) 相关的专利（医药）

登录后查看更多信息

1,159

项与 S1P (York Pharma) 相关的文献（医药）

2024-12-01·International Immunopharmacology

Sphingosine-1-phosphate alleviates Sjögren’s syndrome-like symptoms via inducing autophagy and regulating status of Treg cells in NOD mice

Article

作者: Gao, Chong ; Sun, Lei ; Luo, Jing ; Ni, XiaoHan ; Xue, JiaHui ; Wang, Yanlin ; Qiang, Le ; Feng, Min ; Jin, Yue

BACKGROUNDSjögren' s syndrome (SS) is a chronic autoimmune disease that causes multiple lesions. Regulatory T (Treg) cells play an important role in the maintenance of immune homeostasis. Weakened Treg-cell-mediated immunosuppression may aggravate SS symptoms by inducing lymphocyte infiltration into the salivary glands. Although Treg cell egress from such glands requires sphingosine-1-phosphate (S1P), the specific effects of S1P on SS-like symptoms remain unclear.AIMSTo examine the effect of S1P on SS-like symptoms and the crosstalk between such symptoms and autophagy in non-obese diabetic (NOD) mice.METHODSNOD mice were taken as SS model mice. Balb/c mice served as controls. Serum anti-SSA and anti-SSB antibodies were quantitated via ELISA. Submandibular gland tissues were subjected to haematoxylin-and-eosin staining, and extracts thereof to reverse transcription-polymerase chain reaction. The numbers of Treg cells; and the levels of cytokines, LC3, and SPHK1 were measured via flow cytometry (FCM). The Treg immunosuppression capacity was assessed in co-culture experiments.RESULTCompared to untreated NOD mice, mice treated with S1P exhibited milder disease, and higher numbers of functional Treg cells. FCM revealed that S1P restored LC3 expression in Treg cells, but had little effect on the LC3 levels of Teff cells. RT-PCR showed that S1P increased the expression levels of mRNAs encoding Foxp-3, SPHK1, S1PR1, and LC3 in submandibular glands (SMGs). After administration of PF-543, the disease became aggravated; lymphocyte infiltration into SMGs increased and LC3 expression fell.CONCLUSIONS1P therapy alleviated SS-like symptoms in NOD mice by increasing the number of Treg cells, by restoring Treg cell function, and by positively regulating autophagy via crosstalk. Such therapy may be a new and valuable SS treatment option.

2024-12-01·Immunology Letters

Fingolimod, an antagonist of sphingosine 1-phosphate, ameliorates Sjögren's syndrome by reducing the number of STAT3–induced germinal center B cells and increasing the number of Breg cells

Article

作者: Cho, Mi-La ; Jhun, JooYeon ; Lee, Yeon Su ; Yang, Seung Cheon ; Hwang, Sun-Hee ; Woo, Jin Seok ; Lee, Kun Hee ; Lee, A Ram ; Choi, Jeong Won

BACKGROUNDSjögren's syndrome (SS) is an autoimmune disease caused by infiltrating lymphocytes. FTY720 affects the S1P signaling pathway, which plays a role in T and B cell migration from secondary lymphoid tissues to target organs. In this study, we investigate the regulatory mechanism of FTY720 in the context of SS.METHODFTY720 was given orally every day to NOD mice. The salivary flow rate (SFR) and blood glucose level were assayed every 3 weeks. Histopathological features were investigated at the end of the study. In vitro, FTY720 was added to mouse splenocytes, and changes in the lymphocyte subsets were assessed.RESULTSIn vivo, FTY720 increased the SFR and reduced the blood glucose level. The salivary gland histological score and infiltration of the salivary glands by B and T cells were dramatically decreased. Furthermore, STAT expression in the salivary gland was decreased. In vitro, FTY720 inhibited Th17 cells, while increasing regulatory T (Treg) cells, respectively. Also, FTY720 decreased and increased the numbers of germinal center (GC) B cells and regulatory B cells (Breg cells), respectively. FTY720 decreased the IgG level in culture supernatants. Also, STAT3 activation was decreased by FTY720.CONCLUSIONOur results show the therapeutic potential of FTY720 in the context of SS; FTY720 prevents lymphocyte migration from secondary lymphoid organs to target organs.

2024-11-01·CNS Drugs

Ozanimod: A Review in Relapsing Forms of Multiple Sclerosis

Review

作者: Nie, Tina ; Syed, Yahiya Y ; Syed, Yahiya Y.

Ozanimod (Zeposia^®), an orally administered sphingosine 1-phosphate (S1P) receptor modulator (S1PRM) that is selective for the S1P₁ and S1P₅ receptor subtypes, is approved in the USA for relapsing forms of multiple sclerosis (RMS). In pivotal phase III clinical trials in patients with RMS, ozanimod significantly reduced annualised relapse rates and the number of new or enlarging T2 lesions and gadolinium-enhancing lesions, and was associated with reduced brain volume loss, compared with interferon (IFN)-β1a. However, there were no significant differences in 3- and 6-month disability progression between the groups. Ozanimod was generally well tolerated, with the most common adverse reactions including upper respiratory tract infection and hepatic transaminase elevation. Efficacy and tolerability were sustained over more than 6 years with continued treatment. S1PRM-related adverse events seen with ozanimod are generally manageable with screening and/or monitoring. Notably, ozanimod does not require first-dose cardiac monitoring in the USA. In conclusion, ozanimod is a valuable once-daily oral disease-modifying therapy that extends the available treatment options for patients with RMS.

100 项与 S1P (York Pharma) 相关的药物交易

登录后查看更多信息